TIGIT and neoplasm: By ligand interaction, TIGIT is able to inhibit lymphocytes activity through different mechanisms of action including modulation through its intracellular tail after binding to PVR, induction of PVR signaling in adjacent dendritic or tumor cells, and inhibition of CD226 signaling6.